Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486301 · ClinicalTrials.gov registry record · Phase 1
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
A Phase 1 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT03486301: Completed Phase 1 study, sponsored by Eikon Therapeutics.
NCT03486301 is a Phase 1 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 87 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03486301, a Phase 1 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Primary Outcome
Safety and tolerability of BDB001 as a single agent and in combination with pembrolizumab as measured by the incidence of adverse events and any dose limiting toxicity
Interventions
- DRUG Pembrolizumab
- DRUG BDB001 (EIK1001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 1 |
What the finished NCT03486301 record still lists
NCT03486301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03486301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03486301 about?
NCT03486301 is a clinical study titled "BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab". Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT03486301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2018-02-15. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03486301?
The interventions under investigation include: Pembrolizumab (DRUG), BDB001 (EIK1001) (DRUG).
Who is sponsoring clinical trial NCT03486301?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03486301's enrollment target sits among peer trials
87 651st of 2000 higher than 1,349 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI